MedCity News December 3, 2024
Keros Therapeutics will present Phase 2 data for the drug, elritercept, at the annual meeting of the American Society of Hematology. Meanwhile, the Takeda deal enables Keros to focus on two wholly owned assets, one of which could compete with a Merck drug approved earlier this year.
Takeda Pharmaceutical is expanding its prospects in hematology with a deal for rights to a drug advancing to pivotal testing in a type of blood cancer, giving the Japanese pharmaceutical giant an asset that could potentially compete with a blockbuster Bristol Myers Squibb product.
Takeda is getting elritercept, the lead drug candidate of Keros Therapeutics. Per terms of the deal announced Tuesday, the pharma company is paying $200 million up front for exclusive...
Today's Sponsors
Today's Sponsor